Cargando…
A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro
Cardiotoxicity is the main dose-limiting side effect of doxorubicin in the clinic. Being a free radical producer, doxorubicin affects the heart specifically because of its low antioxidant capacity. Among those antioxidants, catalase is present in very low levels in the heart compared to other organs...
Autores principales: | Abou El Hassan, M A I, Rabelink, M J W E, van der Vijgh, W J F, Bast, A, Hoeben, R C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376857/ https://www.ncbi.nlm.nih.gov/pubmed/14647150 http://dx.doi.org/10.1038/sj.bjc.6601430 |
Ejemplares similares
-
The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro
por: Abou El Hassan, M A I, et al.
Publicado: (2003) -
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007) -
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007) -
The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB
por: Jacobs, H, et al.
Publicado: (2011) -
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
por: Bruynzeel, A M E, et al.
Publicado: (2007)